|
DCF -Bewertung von Raketen Pharmazeutika, Inc. (RCKT)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Rocket Pharmaceuticals, Inc. (RCKT) Bundle
Vereinfachen Sie die Bewertung von Rocket Pharmaceuticals, Inc. (RCKT) mit diesem anpassbaren DCF -Taschenrechner! Mit Real Rocket Pharmaceuticals, Inc. (RCKT) -Fonds und einstellbaren Prognoseeingaben können Sie Szenarien testen und Rocket Pharmaceuticals, Inc. (RCKT) -Fairwert in Minuten aufdecken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -131.6 | -161.7 | -213.7 | -236.6 | -273.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 1.1 | 5.4 | 6.3 | 7.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -132.7 | -167.1 | -220.0 | -243.7 | -273.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 482.7 | 388.7 | 356.4 | 373.2 | 372.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -29.1 | -7.7 | -8.6 | -16.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -139.4 | -167.6 | -217.5 | -243.7 | -273.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -167.3 | -169.9 | -219.8 | -253.1 | -273.2 | .0 | .0 | .0 | .0 | .0 |
| WACC, % | 8.74 | 8.74 | 8.73 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 | 8.74 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -138 | |||||||||
| Equity Value | 138 | |||||||||
| Diluted Shares Outstanding, MM | 95 | |||||||||
| Equity Value Per Share | 1.46 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real RCKT financials.
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Rocket Pharmaceuticals' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- 🔍 Real-Life RCKT Financials: Pre-filled historical and projected data for Rocket Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Rocket Pharmaceuticals’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Rocket Pharmaceuticals’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template featuring Rocket Pharmaceuticals, Inc. (RCKT) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Rocket Pharmaceuticals, Inc. (RCKT) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose Rocket Pharmaceuticals, Inc. (RCKT)?
- Innovative Solutions: Cutting-edge therapies aimed at transforming patient outcomes.
- Expertise in Gene Therapy: A strong focus on developing advanced genetic treatments for rare diseases.
- Commitment to Quality: Rigorous standards ensure the highest level of safety and efficacy in our products.
- Strong Pipeline: A diverse range of promising candidates in various stages of development.
- Backed by Research: Collaborations with leading institutions enhance our scientific credibility.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Rocket Pharmaceuticals stock (RCKT).
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Rocket Pharmaceuticals.
- Consultants: Deliver professional valuation insights on Rocket Pharmaceuticals to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like Rocket Pharmaceuticals are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Rocket Pharmaceuticals.
What the Template Contains
- Historical Data: Includes Rocket Pharmaceuticals' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Rocket Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Rocket Pharmaceuticals' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.